Biocept to Present at H.C. Wainwright Virtual BioConnect Conference

Rhea-AI Summary

Biocept (Nasdaq: BIOC) announced that President and CEO Michael Nall will present at the H.C. Wainwright Virtual BioConnect Conference from January 11-14, 2021. The presentation will be available on the Investor Relations section of the Biocept website starting at 6:00 a.m. Eastern time on January 11. Additionally, Nall will participate in a diagnostics panel discussion on January 12, 2021, at 12:00 p.m. Eastern time, hosted by former FDA Commissioner Scott Gottlieb.

SAN DIEGO, Jan. 4, 2021 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces that President and CEO Michael Nall will present at the H.C. Wainwright Virtual BioConnect Conference being held January 11-14, 2021.  The presentation can be accessed on the Investor Relations section of the Biocept website beginning on January 11, 2021 at 6:00 a.m. Eastern time.

Mr. Nall will also participate in a panel discussion on diagnostics and devices hosted by Scott Gottlieb, M.D., former Food and Drug Administration (FDA) Commissioner and former Centers for Medicare & Medicaid Services (CMS) Senior Advisor.  The panel will be held Tuesday, January 12, 2021 at 12:00 p.m. Eastern time.  The panel presentation will be available live and through the remainder of the conference, and can be accessed by registering for the H.C. Wainwright BioConnect Conference here. 

About Biocept
Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company uses its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. The Company's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. Additionally, Biocept is offering nationwide COVID-19 polymerase chain reaction (PCR) testing to support public health efforts during this unprecedented pandemic. For more information, please visit www.biocept.com.

Investor Contact: 
LHA Investor Relations
Jody Cain
Jcain@lhai.com 
310-691-7100

View original content to download multimedia:http://www.prnewswire.com/news-releases/biocept-to-present-at-hc-wainwright-virtual-bioconnect-conference-301199846.html

SOURCE Biocept, Inc.

FAQ

When will Biocept present at the H.C. Wainwright Virtual BioConnect Conference?

Biocept will present at the H.C. Wainwright Virtual BioConnect Conference from January 11-14, 2021.

Who is presenting for Biocept at the conference?

President and CEO Michael Nall will present for Biocept at the conference.

What time is Biocept's presentation at the H.C. Wainwright Virtual BioConnect Conference?

Biocept's presentation will be accessible starting at 6:00 a.m. Eastern time on January 11, 2021.

When is the panel discussion featuring Michael Nall at the conference?

Michael Nall will participate in a panel discussion on January 12, 2021, at 12:00 p.m. Eastern time.

Who is hosting the panel discussion that Michael Nall will participate in?

The panel discussion will be hosted by former FDA Commissioner Scott Gottlieb.